Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document the company as a Nasdaq-listed foreign private issuer operating a Singapore-based healthcare business focused on non-invasive, preventive and longevity-oriented services in Asia. Form 6-K reports disclose business updates involving stem cell and cellular therapy arrangements, commercial distribution rights, and related healthcare platform expansion.
The filing record also covers capital-structure and governance matters, including ordinary share offerings under a Form F-3 registration statement, warrant issuances, amendments, repurchase and cancellation, a reverse stock split, Nasdaq market-value compliance notices, and amendments to the company's BVI constitutional documents.
EUDA Health Holdings announced a board change. Independent director Prof. Wong Kong Yew resigned effective October 23, 2025, including his roles as Chairman of the Compensation Committee and member of the Audit and Nomination Committees. The company stated his resignation was not due to any disagreement or dispute with the company or its Board.
On October 24, 2025, the Board appointed Huang Bo as an independent director, Chairman of the Compensation Committee, and member of the Audit and Nomination Committees. The Board determined Mr. Huang is independent under Nasdaq rules and Rule 10A-3. It reviewed his role at entities linked to a EUDA business partner and concluded this would not interfere with his independent judgment. The company also noted there are no related-party transactions involving Mr. Huang requiring disclosure.
EUDA Health Holdings Limited submitted a Form 6-K as a foreign private issuer for October 2025. The filing notes that on October 23, 2025, the company issued a press release, which is attached as Exhibit 99.1, and was signed by Chief Executive Officer Alfred Lim.
EUDA Health Holdings Limited updated the terms of its August 1, 2025 $1,000,000 convertible promissory note with an institutional investor. The investor has already converted $837,500 of this note into 569,859 ordinary shares and previously received 41,620 shares at $0.901 per share under a letter agreement.
Under a new amendment signed on October 2, 2025, the investor agreed not to convert the remaining $162,500 balance until after October 31, 2025. On that date, the investor may either convert the $162,500 into 81,250 ordinary shares at $2.00 per share or request cash repayment by November 17, 2025. EUDA also reiterates that it does not intend to request the sale of additional notes under the existing purchase agreement.
EUDA Health Holdings Limited submitted a Form 6-K as a foreign private issuer to provide investors with its financial information for the six months ended June 30, 2025. The filing states that the company is furnishing unaudited condensed consolidated balance sheets as of June 30, 2025 and December 31, 2024, along with unaudited condensed consolidated statements of operations and comprehensive loss for the comparable six-month periods in 2025 and 2024.
The submission also includes an operating and financial review and prospects section discussing these interim results. This interim package gives a mid-year view of EUDA Health Holdings Limited’s financial position, performance, and management’s commentary between its annual reports on Form 20-F.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Limited reports a new agreement with its institutional investor around an existing convertible note. The investor originally agreed to purchase up to $10,000,000 in convertible promissory notes and had already bought a $1,000,000 note that converts into ordinary shares at an 85% discount each time it converts. The company now has delivered 41,620 ordinary shares at a conversion price of $0.901 per share and both parties have mutually waived past breaches of the note and related agreement. In return, the investor agreed not to make further conversions until December 15, 2025, unless EUDA’s Nasdaq closing price reaches $2.00 or higher for three consecutive trading days. EUDA also states it does not intend to purchase any additional notes under the note purchase agreement.